Bristol Myers Squibb (BMY) EBT Margin (2009 - 2026)

Bristol Myers Squibb has disclosed EBT Margin across 18 years of filings, most recently posting 28.2% for Q1 2026.

• In Q1 2026, EBT Margin rose 168.0% year-over-year to 28.2%; the TTM figure through Mar 2026 stood at 19.79% (up 697.0% YoY), while the FY2025 annual figure was 19.36%, up 3670.0% from the prior year.
• EBT Margin advanced to 28.2% in Q1 2026, from 11.76% in the prior quarter.
• Over the last five years, EBT Margin for BMY reached as high as 28.2% in Q1 2026 and fell as low as 97.06% in Q1 2024.
• The 5-year median for EBT Margin is 16.3% (2022), against an average of 10.44%.
• Annual changes were most pronounced in 2024 — EBT Margin tumbled 12149 bps — and 2025, when it soared 12358 bps.
• A 5-year view of EBT Margin shows it stood at 16.3% in 2022, then slipped by 11 bps to 14.59% in 2023, then plunged by 90 bps to 1.42% in 2024, then soared by 729 bps to 11.76% in 2025, then soared by 140 bps to 28.2% in 2026.
• According to Business Quant data, EBT Margin over the past three periods registered 28.2%, 11.76%, and 25.48% for Q1 2026, Q4 2025, and Q3 2025 respectively.